martes, 17 de noviembre de 2026

Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns LSE professor Ken Shadlen argues drugmakers should ready licensing plans now

https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/ By Ed SilvermanNov. 16, 2026 Pharmalot Columnist, Senior Writer Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer.

No hay comentarios:

Publicar un comentario